



August 02, 2018

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Sub : Execution of Deed of Admission and Retirement of Partner, by and between HealthCare Global Enterprises Limited (“HCG” or “the Company”), Apex Criticare LLP (“Apex Criticare”), Niruja Product Development and Healthcare Research Private Limited (“Niruja”) and Apex HCG Oncology Hospitals LLP (“the LLP”), in connection with the partnership rights in the LLP.

Ref : Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code : NSE Scrip Code: HCG; BSE Scrip Code: 539787

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we wish to inform you that the Company has entered into a Deed of Admission and Retirement of Partner (“*the Agreement*”) on August 01, 2018 (“*Execution Date*”), with Apex Criticare, Niruja and the LLP, with respect to the retirement/exit of Apex Criticare as a partner in the LLP, and the consequent induction of Niruja as a new partner in the LLP.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015

1. Name of the Parties with whom the agreement is entered into:

The Agreement has been entered into by and between the Company, Apex Criticare, Niruja and the LLP.

2. Purpose of entering into the Agreement.

The Agreement has been entered into by the parties to record the terms and condition with regard to the retirement/exit of Apex Criticare as a partner in the LLP; and to set out the relationship between the Company and Niruja in connection with the admission of Niruja as a new partner of the LLP.



3. *Shareholding, if any, in the entity with whom the agreement is executed;*

On and from the Execution Date, Apex Criticare has exited from the LLP as a partner. The partners of the LLP from the Execution Date are HCG and Niruja, with a capital contribution in the ratio of 99.9% and 0.1%, respectively.

4. *Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;*

- a) On and from the Execution Date, Apex Criticare has ceased to be a partner of the LLP and the designated partner nominated by Apex Criticare has ceased to be a designated partner of the LLP.
- b) Niruja has been admitted as a partner of the LLP, from the Execution Date.
- c) HCG and Niruja have the right to nominate one Designated Partner each in the LLP.
- d) A new partner (“the incoming partner”) can be inducted only with the prior written consent of all the existing partners.
- e) HCG has the right to take decisions on all matters of the LLP, other than those specifically provided as reserved matters in the Agreement.

5. *Whether, the said parties are related to promoter/promoter group/group companies in any manner;*

None of the parties are related to promoter/promoter group/ group companies in any manner.

6. *Whether the transaction would fall within related party transactions?*

Niruja is a wholly owned subsidiary of the Company and hence a related party.

7. *In case of issuance of shares to the parties, details of issue price, class of shares issued;*

Not Applicable.

8. *Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;*

Not Applicable

9. *In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):*

- a) name of parties to the agreement;

Refer to the response provided under Sl. No.1 above



b) *nature of the agreement;*

Refer to the response provided under Sl. No.2 above

c) *date of execution of the agreement;*

The Agreement has been executed on August 01, 2018

d) *details of amendment and impact thereof or reasons of termination and impact thereof.*

On and from the Execution Date, Apex Criticare has retired from the LLP and have ceased to be a partner of the LLP. Accordingly, the Limited Liability Partnership Agreement dated April 18, 2013 (including amendments made thereof) entered into by the Company and Apex Criticare as partners of the LLP, with a capital contribution ratio of 50.1% and 49.9%, respectively, for operating HCG Apex Cancer Centre, a comprehensive oncology hospital in Borivali, Mumbai, has been terminated. Consequent to the retirement/exit of Apex Criticare, Niruja has been admitted as the other partner in the LLP; and has entered into a new LLP Agreement with the Company, effective from the Execution Date.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer